The pharmacogenetics of coumarin therapy

Deepak Voora; Howard L. McLeod; Charles Eby; Brian F. Gage

doi:10.2217/14622416.6.5.503

The pharmacogenetics of coumarin therapy

Deepak Voora, Howard L. McLeod, Charles Eby, Brian F. Gage

Research output: Contribution to journal › Review article › peer-review

89 Scopus citations

Abstract

Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.

Original language	English
Pages (from-to)	503-513
Number of pages	11
Journal	Pharmacogenomics
Volume	6
Issue number	5
DOIs	https://doi.org/10.2217/14622416.6.5.503
State	Published - Jul 2005

Keywords

Acenocoumarol
CYP enzyme system
Genetic
Pharmacogenetics
Phenprocoumon
Polymorphism
Warfarin

Access to Document

10.2217/14622416.6.5.503

Cite this

@article{83158b45d76d47529cc428feca2b0528,

title = "The pharmacogenetics of coumarin therapy",

abstract = "Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.",

keywords = "Acenocoumarol, CYP enzyme system, Genetic, Pharmacogenetics, Phenprocoumon, Polymorphism, Warfarin",

author = "Deepak Voora and McLeod, {Howard L.} and Charles Eby and Gage, {Brian F.}",

year = "2005",

month = jul,

doi = "10.2217/14622416.6.5.503",

language = "English",

volume = "6",

pages = "503--513",

journal = "Pharmacogenomics",

issn = "1462-2416",

number = "5",

}

TY - JOUR

T1 - The pharmacogenetics of coumarin therapy

AU - Voora, Deepak

AU - McLeod, Howard L.

AU - Eby, Charles

AU - Gage, Brian F.

PY - 2005/7

Y1 - 2005/7

N2 - Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.

AB - Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.

KW - Acenocoumarol

KW - CYP enzyme system

KW - Genetic

KW - Pharmacogenetics

KW - Phenprocoumon

KW - Polymorphism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=23044438068&partnerID=8YFLogxK

U2 - 10.2217/14622416.6.5.503

DO - 10.2217/14622416.6.5.503

M3 - Review article

C2 - 16014000

AN - SCOPUS:23044438068

SN - 1462-2416

VL - 6

SP - 503

EP - 513

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 5

ER -

The pharmacogenetics of coumarin therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this